在日本,Difelikefalin用于血液透析患者的
Ichiei Narita1, Yoshiharu Tsubakihara2, Naoko Takahashi3
1Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
NEJM evidence
|February 6, 2024
概括
在日本的血液透析患者中,difelikefalin有效地减少了. 这种治疗改善了那些经历中度至严重的人的生活质量.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学 是一个学科.
- 皮肤病学 皮肤病学
背景情况:
- 迪菲利克法林 (Difelikefalin) 是卡帕类阿片类受体激活剂,在美国已被批准用于治疗血液透析相关的.
- 对于其在非美国人口中进行透析后静脉注射的证据有限.
研究的目的:
- 评估静脉注射的利克法林在接受维护血液透析的日本患者的疗效和安全性.
- 评估其对的严重程度和生活质量的影响.
主要方法:
- 在日本进行了一项双盲,安慰剂控制的第三期试验.
- 178名中度至重度的患者随机分配给接受安慰剂或迪菲利克法林 (0.5μg/kg IV) 每周三次,持续6周.
- 主要终点是第4周最严重的强度数值评分表 (NRS) 评分的变化.
主要成果:
- 与安慰剂相比,difelikefalin显示NRS得分在统计学上显著降低 (差异为-0.97,P<0.001).
- 在二次生命质量终点中也观察到改善.
- 与治疗相关的不良事件发生在15%的difelikefalin组中,主要是胃肠道问题.
结论:
- 静脉注射的difelikefalin有效地减少了日本血液透析患者的.
- 治疗还可以改善生活质量.
- 安全性概况与之前的研究结果一致,主要是胃肠道不良事件.
相关概念视频
01:27Dialysis
314
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
314
01:11Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
01:17Drugs for Treatment of Diarrhea-Predominant IBS
175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381